Treating neurological illnesses is challenging because the blood-brain barrier hinders therapeutic medications from reaching the brain. Recent advances in polymeric nanocarriers (PNCs), which improve medication permeability across the blood-brain barrier, may influence therapy strategies for neurological diseases. PNCs have several ways to deliver medications to the nervous system. This review article provides a summary of the parts and manufacturing methods involved in making PNCs. Additionally, it highlights the elements that result in PNCs having enhanced blood-brain barrier penetration. A combination of passive and active targeting strategies is used by PNCs intended to overcome the blood-brain barrier. Among these are micellar structures, nanogels, nanoparticles, cubosomes, and dendrimers. These nanocarriers, which are functionalized with certain ligands that target BBB transporters, enable the direct delivery of drugs to the brain. Mainly, the BBB prevents medications from entering the brain. Understanding the BBB's physiological and anatomical characteristics is necessary to get over this obstacle. Preclinical and clinical research demonstrates the safety and effectiveness of these PNCs, and their potential use in the treatment of neurological illnesses, including brain tumors, Parkinson's disease, and Alzheimer's disease, is discussed. Concerns that PNCs may have about their biocompatibility and possible toxicity are also covered in this review article. This study examines the revolutionary potential of PNCs in CNS drug delivery, potential roadblocks, ongoing research, and future opportunities for PNC design progress. PNCs open the door to more focused and efficient treatment for neurological illnesses by comprehending the subtleties of BBB penetration.
Alzheimer's disease (AD) remains one of the hardest neurodegenerative diseases to treat due to its enduring cognitive deterioration and memory loss. Despite extensive research, few viable treatment approaches have been found; these are mostly due to several barriers, such as the disease's complex biology, limited pharmaceutical efficacy, and the BBB. This presentation discusses current strategies for addressing these therapeutic barriers to enhance AD treatment. Innovative drug delivery methods including liposomes, exosomes, and nanoparticles may be able to pass the blood-brain barrier and allow medicine to enter specific brain regions. These innovative strategies of medicine distribution reduce systemic side effects by improving absorption. Moreover, the development of disease-modifying treatments that target tau protein tangles, amyloid-beta plaques, and neuroinflammation offers the chance to influence the course of the illness rather than only treat its symptoms. Furthermore, gene therapy and CRISPR-Cas9 technologies have surfaced as potentially groundbreaking methods for addressing the underlying genetic defects associated with AD. Furthermore, novel approaches to patient care may involve the utilization of existing medications having neuroprotective properties, such as those for diabetes and cardiovascular conditions. Furthermore, biomarker research and personalized medicine have made individualized therapy approaches possible, ensuring that patients receive the best care possible based on their unique genetic and molecular profiles.
1 April 2026 in Current Psychiatry Research and Reviews
Artificial Intelligence (AI) is mainly utilized to measure stress, anxiety, and overall mental well-being, but it is still under evaluation. This review aims to address some of the inadequacies of current healthcare practices through the utilization of AI technology for monitoring, diagnosing, and transforming mental health conditions. The application of machine learning algorithms and natural language processing techniques to assess speech, physiological indicators, and behavioral patterns is the essence of the AI approach. These AI-based algorithms enable the detection of subtle and often imperceptible signs of psychological distress, which conventional clinical assessments find difficult to analyze. The application of speech analysis to detect changes in pitch, speed, and tone that might be connected to feelings of depression or anxiety. Similarly, sentiment analysis and face recognition technologies are applied to textual data and facial expressions to discern emotional states. Incorporating the importance of ethical and privacy concerns, these AI modules potentially offer unparalleled objectivity and accuracy in mental health assessments. AI also raises grave issues around data security and the ethical use of personal information, as it depends on the development of AI technologies and applications, significantly impacting their uptake and effectiveness. The key advantage of AI is the ability to provide ongoing, real-time mental health monitoring by offering a more flexible and dynamic approach to mental health therapy. Overall, this article provides a comprehensive overview of the revolutionary potential of AI in mental health assessment by encapsulating the cutting-edge applications and considerable critical ethical concerns to provide effective and efficient mental health treatment universally.
Cancer therapies have advanced significantly, yet traditional treatments still confront obstacles, such as systemic toxicity and drug resistance. Nanotechnology plays a pivotal role in addressing these issues, particularly through the development of polymer nanocomposites (PNCs). PNCs are hybrid materials composed of a polymer matrix embedded with nanoscale fillers. These composites can be classified based on the type of matrix (ceramic, metal, or polymer) and their structural properties (exfoliated or intercalated forms). Synthesis methods, such as solvent casting and in situ polymerization, ensure the uniform dispersion of nanoparticles within the polymer matrix. PNC-based drug delivery systems are categorized into two types: passive targeting, which leverages the enhanced permeability and retention (EPR) effect, and active targeting, which relies on ligand-receptor interactions. In the pharmaceutical industry, recent developments in nanocomposite-based systems have demonstrated great promise, especially in terms of improving medication solubility, stability, and bioavailability while reducing adverse effects. These methods use nanoparticles embedded in a matrix to increase drug delivery, addressing issues, such as poor solubility and limited bioavailability associated with conventional therapies. Before these novel medicines are widely used, clinical studies are essential for assessing their safety and effectiveness and making sure they adhere to legal requirements. Furthermore, the growth of patents pertaining to nanocomposites indicates continued study and advancement in this field, emphasizing nanocomposites’ potential uses in a range of medical conditions. Nanocomposites are anticipated to transform drug delivery methods and make a substantial contribution to current medicine as research advances.
1 November 2025 in Current Signal Transduction Therapy
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms such as tremors, stiffness, and bradykinesia, as well as non-motor symptoms like cognitive impairment and mood swings. PD is a multifactorial disease comprised of environmental and genetic etiologies. In addition to family history, Variants in the LRRK2 gene are important as they represent the most common cause of familial PD and are also associated with some sporadic cases. The underlying causes of PD are also numerous and can be divided into a variety of environmental and genetic factors. This is the most relevant part because the LRRK2 gene Variant is one of the most common causes of familial Parkinson's disease, as well as contributing to sporadic cases beyond hereditary factors. Pathogenic LRRK2 variants result in the dysfunction of LRRK2, disrupting cellular pathways and potentially driving neurodegeneration. The purpose of the current study was to examine in depth the complex network of LRRK2- regulated signalling pathways and how they collectively modulate changes in neuronal survival and function. These LRRK2 variants are causing cell homeostasis disturbances due to dysfunction of interaction between key proteins such as α-synuclein and tau that have been implicated in Parkinson's development. In addition, we will explore what other therapies could be targeted to mitigate the role of LRRK2-mediated processes in PD, such as kinase inhibitors and other process- targeted treatments.